NFKB1 anticorps (C-Term)

N° du produit ABIN6263615

Détail du produit anti-NFKB1 anticorps

Antigène: NFKB1 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 1 (NFKB1))

Épitope: C-Term

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp NFKB1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Specificité: NF kappaB p105/p50 Antibody detects endogenous levels of total NF kappaB p105/p50.

Homologie: Bovine,Horse,Sheep,Rabbit,Dog,Chicken,Xenopus

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogène: A synthesized peptide derived from human NF kappaB p105/p50, corresponding to a region within C-terminal amino acids.

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20 °C. Stable for 12 months from date of receipt.

Date de péremption: 12 months

Détails sur NFKB1

Antigène: NFKB1 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 1 (NFKB1))

Autre désignation: NFKB1 (NFKB1 Produits)

Synonymes: anticorps GKLP, anticorps NKTL, anticorps NTKL, anticorps P105, anticorps TAPK, anticorps TEIF, anticorps TRAP, anticorps EBP-1, anticorps KBF1, anticorps NF-kB1, anticorps NF-kappa-B, anticorps NF-kappaB, anticorps NFKB-p105, anticorps NFKB-p50, anticorps NFkappaB, anticorps p105, anticorps p50, anticorps NF-kB, anticorps NF-KB1, anticorps ebp-1, anticorps kbf1, anticorps nf-kappa-b, anticorps nf-kappaB, anticorps nfkb-p105, anticorps nfkb-p50, anticorps NF-kappaB1, anticorps p50/p105, anticorps BICDR-1, anticorps bicdr1, anticorps ccdc64, anticorps SCY1 like pseudokinase 1, anticorps nuclear factor kappa B subunit 1, anticorps nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 L homeolog, anticorps nuclear factor NF-kappa-B p105 subunit, anticorps nucleoporin 107, anticorps nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105, anticorps nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, anticorps SCYL1, anticorps NFKB1, anticorps Nfkb1, anticorps nfkb1.L, anticorps CpipJ_CPIJ012236, anticorps Nup107, anticorps nfkb1

Sujet:

Description: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling, active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.

Gene: NFKB1

Poids moléculaire: 105kDa

ID gène: 4790

UniProt: P19838

Pathways: Signalisation p53, Signalisation NF-kappaB, Signalisation RTK, TCR Signaling, Signalisation TLR, Fc-epsilon Receptor Signaling Pathway, Neurotrophin Signaling Pathway, Activation of Innate immune Response, Myometrial Relaxation and Contraction, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Toll-Like Receptors Cascades, BCR Signaling, S100 Proteins